FINWIRES · TerminalLIVE
FINWIRES

TYO:4578

10 stories mentioning TYO:4578Updated 7d ago

Every FINWIRES story that references TYO:4578, newest first.

Asia

Otsuka's VOYXACT Halts Kidney Function Decline in Phase 3 Trial

Otsuka Holdings (TYO:4578) said new two-year data from its Phase 3 Visionary trial showed that VOYXACT effectively stopped kidney function decline in patients with IgA nephropathy (IgAN), a progressive kidney disease.Patients treated with VOYXACT maintained stable kidney function at near-normal levels, while those on placebo continued to experience significant deterioration, according to a Tokyo bourse filing on Tuesday.The drug demonstrated a strong safety profile over two years, with no new safety concerns and even lower rates of serious infections compared to the placebo group.These results complete the Phase 3 study and support Otsuka's ongoing application to the U.S. FDA for full traditional approval of VOYXACT.

TYO:4578
Asia

Japanese Shares Rise on Global Tech Rebound; Oil Falls on Improved Supply Flows

Japanese stocks gained as global technology stocks rallied, renewing investor hopes on artificial intelligence-related investments following a weeklong sell-off in chip stocks.The benchmark Nikkei 225 closed up 2,494.59 points, or 4.03%, at 64,362.02.Oil prices declined on improved crude and liquefied natural gas supply flows through key shipping routes even as escalating tensions between the US and Iran kept the Middle East outlook uncertain.On the corporate side, Murata Manufacturing (TYO:6981) posted a 64% year-over-year jump in attributable profit for the fiscal first quarter to 81.4 billion yen from 49.7 billion yen.Also, Otsuka (TYO:4578) raised its 2026 attributable profit forecast to 355 billion yen from 265 billion yen previously estimated, according to a Tokyo Stock Exchange filing on Friday.

Nikkei 225TYO:4578TYO:6981
Asia

Otsuka Raises 2026 Earnings Forecast on Pharma Growth

Otsuka (TYO:4578) raised its 2026 attributable profit forecast to 355 billion yen from 265 billion yen previously estimated.The healthcare conglomerate now expects basic earnings per share of 675.47 yen, up from 504.94 yen previously, according to a Tokyo bourse filing on Friday.Revenue forecast for the year was lifted to 2.725 trillion yen from 2.520 trillion yen.The upward revision was driven by continued growth in key drugs including Rexulti, Lonsurf and Voyxact, later-than-expected arrival of generic versions of Jynarque in the U.S. and Abilify Maintena in Europe and strong nutraceutical sales, as well as a weaker yen.

TYO:4578
Asia

Japanese Stocks Fall As Investors Turn Cautious on AI Investments Amid Chinese Competition

Japanese stocks fell, marking the worst global chip sell-off, as concerns over piling artificial intelligence investments and their sustainability fueled fears that growing competition from China could derail the AI infrastructure boom.The benchmark Nikkei 225 closed down 2,566.27 points, or 3.95%, at 62,364.92.Oil prices fell, and bonds gained over the temporary US-Iran ceasefire de-escalating hostilities and easing inflation pressure.On the corporate side, Otsuka Holdings (TYO:4578) has revised its forecast for first-half profit attributable to owners of the company to 215 billion yen, up 68% from 128 billion yen previously, according to a Tokyo bourse filing on Tuesday.Also, Hulic (TYO:3003) posted an 11% year-over-year increase in profit attributable to owners of the parent to 49.9 billion yen in the first half, up from 44.9 billion yen.

Nikkei 225TYO:3003TYO:4578
Asia

Otsuka Holdings Raises H1 Earnings Forecast

Otsuka Holdings (TYO:4578) has revised its forecast for first-half profit attributable to owners of the company to 215 billion yen, up 68% from 128 billion yen previously, according to a Tokyo bourse filing on Tuesday.The healthcare conglomerate now expects EPS of 407.90 yen, up from 243.07 yen previously.The revenue forecast was increased to 1.332 trillion yen from 1.218 trillion yen.The revision was due to the strong performance of the company's businesses, driven by the later-than-estimated arrival of the generic versions of Jynarque in the US and Abilify Maintena in Europe, solid results from Voyxact, Rebuilt, and Lonsurf, as well as a positive foreign exchange rate dynamic.

TYO:4578
Asia

Jefferies Adjusts Otsuka Holdings' Price Target to 12,700 Yen From 12,500 Yen, Keeps at Buy

Otsuka Holdings (TYO:4578) has an average rating of overweight and mean price target of 12,940.77 yen, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

TYO:4578
Asia

Otsuka Holdings Repurchases 7.75 Billion Yen Worth of Shares in June

Otsuka Holdings (TYO:4578) repurchased 736,700 shares between June 1 and June 30 through market purchases for 7.75 billion yen, according to a Wednesday filing on the Tokyo Stock Exchange.The repurchases are part of an ongoing share buyback program originally authorized by the board of directors on Feb. 13. The program permits the acquisition of up to 7 million shares at a purchase price of 50 billion yen.With this, Otsuka has repurchased over 2.8 million shares to date for 29.91 billion yen. The buyback launched on Feb. 16 and runs through Dec. 23.

TYO:4578
Research

SMBC Nikko Upgrades Otsuka Holdings to Outperform from Neutral; Price Target is 12,500 Yen

Otsuka Holdings (TYO:4578) has an average rating of overweight and mean price target of 12,713.85 yen, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

TYO:4578
Asia

Otsuka Holdings' Profit Rises 16% in Q1

Otsuka Holdings' (TYO:4578) profit attributable to owners of the parent climbed 16% to 98.3 billion yen for the first quarter from nearly 85 billion yen a year earlier.The pharmaceutical company's basic earnings per share increased to 186.31 yen from 158.57 yen a year ago, according to a Tokyo bourse filing on Tuesday.Revenue increased by 8.2% to 630.3 billion yen for the three months ended March 31 from 582.8 billion yen in the prior year.For the year ending Dec. 31, the company expects attributable profit of 265 billion yen, basic EPS of 504.94 yen, and revenue of 2.520 trillion yen.Otsuka Holdings plans to pay interim and year-end dividends of 70 yen, each, for the year, which is the same amount paid in the year-ago period.

TYO:4578
Asia

Jefferies Adjusts Otsuka Holdings' Price Target to 12,500 Yen From 11,000 Yen, Keeps at Buy

Otsuka Holdings (TYO:4578) has an average rating of overweight and mean price target of 11,736.92 yen, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

TYO:4578

Track with the FINWIRES app suite

FolioX
FolioX
Track TYO:4578 in your portfolio
WheelAI
WheelAI
Analyze TYO:4578 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on TYO:4578